



Lower GI Medical Oncology Service





Operational Structure

Most referrals come from surgical teams outside The Christie. Local MDTs assess patients' needs and surgical intervention is performed locally. The Christie Lower GI Surgical team accept referrals for complex primary tumours, recurrent pelvic tumours and in case where cytoreduction and HIPEC are considered (both colorectal adenocarcinoma and PMP). Chemotherapy is delivered centrally at Christie as well as at a number of peripheral sites including Royal Oldham, Stepping Hill, Royal Albert Edward Infirmary (Wigan) and Leighton (Crewe) hospitals. Patients are also treated at Mobile Chemotherapy Units (MCU) where possible.

MDT meetings

MDTs across Greater Manchester attended by Lower GI Medical Oncologists:

All new lower GI patients are discussed/assessed through Multi-disciplinary Team Meetings at the following Hospitals:

- Central Manchester University Hospital (incorporating Trafford General Hospital)
- Wythenshawe Hospital
- Pennine Acute Hospitals (incorporating North Manchester General Hospital, Royal Oldham Hospital, Rochdale Infirmary, and Fairfield Hospital)
- Tameside Hospital

- Stepping Hill Hospital, Stockport
- Leighton Hospital, Crewe
- Christie Hospital
- Royal Albert Edward Infirmary, Wigan

Clinical Oncology, rather than medical oncology, consultants attend the colorectal MDTs at the following hospitals:

- Salford Royal Infirmary
- Macclesfield Hospital
- Royal Bolton Hospital

Specialist MDT meetings

The Pseudomyxoma surgical practice at the Christie Hospital is supported by Dr Braun and Dr Mullamitha who attend the Pseudomyxoma MDT meetings. Dr Braun attends the Pelvic MDT for complex surgical cases.

In 2014 the HPB surgical practice for Greater Manchester has centralised at CMFT and a weekly liver metastases MDT has been set up which Dr Braun and Dr Mullamitha jointly support.

Personnel

Consultants	
	Dr Michael Braun
	Dr Saifee Mullamitha
	Dr Jurjees Hasan



	Dr Greg Wilson
Clinical Nurse Specialist	Julie Brewer Sarah Dunne
Nurse Clinician	Olive Craven Janette Beech
Research team	Delyth McEntee – Team Leader Jackie Connell Jo Allen Camille Cooney

Activity

Approximately ~700 new patients are referred per annum to the lower GI Medical Oncology service.

The breakdown of cases is approximately:

Adjuvant treatment: 30%

Neo-adjuvant treatment: 20%

Palliative systemic treatment: 40%

Supportive care only: 10%

Service Development 2013/14

A business case was developed for an additional Clinical Nurse Specialist in 2013 and

a Nurse Clinician in 2014. Sarah Dunne and Janette Beech have been appointed to these roles which are essential to support the management of patients. Nurse led and telephone follow-up clinics have been set up subsequent to these appointments.

A locum Consultant in Medical Oncology has been appointed taking referrals from the Royal Edward Albert Infirmary, Wigan with the aim of developing the chemotherapy service at that site.

Dr M. Braun is research lead and Medical Oncology representative for the Colorectal Pathway Board. In these roles he has written regional guidance for RAS mutation testing in collaboration with the Genomic Medicine department at St.Marys' Hospital and the finance department at Christie.

Dr Braun in collaboration with colleagues has written the regional policy for Mismatch Repair assessment in colorectal cancer.

Development of MDTs – During 2014 Dr Braun and Dr Mullamitha have both started supporting 2 regional specialist MDT meetings for Pseudomyxoma and colorectal liver metastases respectively.



[Outcomes – Click Here](#)





Peer Reviewed Publications 2013/14

Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis.

Dan Rosmarin, Claire Palles, David Church, Enric Domingo, Angela Jones, Elaine Johnstone, Haitao Wang, Sharon Love, Patrick Julier, Claire Scudder, George Nicholson, Anna Gonzalez-Neira, Miguel Martin, Daniel Sargent, Erin Green, Howard McLeod, Ulrich M. Zanger, Matthias Schwab, Michael Braun, Matthew Seymour, Lindsay Thompson, Benjamin Lacas, Valérie Boige, Nuria Ribelles, Shoaib Afzal, Henrik Enghusen, Søren Astrup Jensen, Marie-Christine Etienne-Grimaldi, Gérard Milano, Mia Wadelius, Bengt Glimelius, Hans Garmo, Milena Gusella, Thierry Lecomte, Pierre Laurent-Puig, Eva Martinez-Balibrea, Rohini Sharma, Jesus Garcia-Foncillas, Zdenek Kleibl, Alain Morel, Jean-Pierre Pignon, Rachel Midgley, David Kerr and Ian Tomlinson.

JCO Apr 1, 2014:1031-1039.

A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer.

Tamas Hickish, Jim Cassidy¹, David Propper, Ian Chau, Stephen Falk, Hugo Ford, Tim Iveson, Michael Braun, Vanessa Potter, Iain R. Macpherson, Helen Finnigan, Chooi Lee, Hilary Jones, and Mark Harrison.

European Journal of Cancer, Volume 50, Issue 18, Pages 3136–3144.

Management of colorectal cancer presenting with synchronous liver metastases.

Siriwardena AK, Mason JM, Mullamitha S, Hancock HC, Jegatheeswaran S.

Nat Rev Clin Oncol. 2014 Aug;11(8):446-59.

Evaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer. Khoja L, Kumaran G, Zee YK, Murukesh N, Swindell R, Saunders MP, Clamp AR, Valle JW, Wilson G, Jayson GC, Hasan J. J Clin Gastroenterol. 2014 May-Jun;48(5):430-4.

Mortality within 30 days following systemic anti-cancer therapy, a review of all cases over a 4 year period in a tertiary cancer centre. Khoja L, McGurk A, O'Hara C, Chow S, Hasan J. Eur J Cancer. 2015 Jan;51(2):233-40.



Circulating tumour cell enumeration in a Phase II trial of a four-drug regimen in advanced colorectal cancer. Krebs, MG, Backen A, Gollins S, Chau I, Hasan J, Valle JW, Morris K, Beech J, Ashcroft L, Saunders MP, Dive C. Clin Colorectal Cancer 2014. In Press. doi:10.1016/j.clcc.2014.12.006

Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tian Y, Sidhu R. Ann Oncol. 2014 Jan;25(1):107-16.

Trials activity.

There is a close collaborative working occurring between the departments of medical and clinical oncology to recruit patients to a range of commercial and NCRN trials. Studies currently open are listed below.

Rectal Cancer

ARISTOTLE - A phase III trial comparing standard versus novel CRT as pre-operative treatment for MRI defined locally advanced rectal cancer

Adjuvant setting

FOXTROT - Fluoropyrimidine, Oxaliplatin and Targeted-Receptor pre-Operative Therapy for patients with high-risk, operable colon cancer

ADD ASPIRIN - A phase III double-blind, placebo-controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours

Metastatic setting

PULMICC - A Randomised trial of Pulmonary Metastasectomy in Colorectal Cancer



FOCUS4 – Molecular selection of therapy in colorectal cancer: a molecularly stratified randomised trial programme

PANTHER - AZD8931, an inhibitor of EGFR, ERBB2 and ERBB3 signalling, in combination with FOLFIRI: A Phase I/II study to determine the importance of schedule and activity in colorectal cancer

CAPITAL - A phase I/II dose finding study evaluating the safety and tolerability of CApecitabine and aflibercept in patients with unresectable metastatic colorectal cancer deemed unsuitable for doublet/triplet chemotherapy.

IMPALA-Trial - Evaluation of an immunomodulatory maintenance treatment in patients with metastatic colorectal cancer with tumor reduction during induction treatment.

LUME - A double-blind, randomised, placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies.

XILONIX - A Double Blind, Placebo Controlled, Pivotal Phase III Study Evaluating Xilonix™ in Symptomatic Colorectal Cancer Patients Refractory To Standard Therapy

Clinical Audit Activity

Pulmonary Metastatectomy in Colorectal Cancer – lead Dr M. Braun

Second Line Aflibercept in Colorectal Cancer – lead Dr S Mullamitha

Utilisation of adjuvant chemotherapy in Colorectal Cancer – Lead Prof A. Renehan with contribution from Dr M. Braun and Dr S. Mullamitha

VTE in upper and lower GI cancers - lead Dr J. Hasan

Carcinoma of unknown primary: features and outcomes of patients managed in a large UK centre – lead Dr. J. Hasan

30-day SACT mortality – lead Dr J. Hasan

Clinical trial participation and outcomes in colorectal cancer. A case control study. – lead Dr J. Hasan



Educational, Teaching and Training Activity

Medical School:

Dr Braun delivers an induction lecture and a lecture on colorectal cancer to 5th year medical students on placement at the Christie from August to December each year.

All medical oncology consultants regularly have medical students attending their clinics.

Dr Braun and Dr Mullamitha both supervise final year medical students PEP and SSC modules as well as clinical shadowing placements.

Junior Doctors:

Dr Mullamitha is Junior Doctor lead and attends a weekly meeting with Foundation and Core Medical Trainees. He is lead for Academic Foundation Training at the Christie Hospital. He is a clinical supervisor of CMT trainees and Junior Oncology Fellows. Dr Braun is a clinical supervisor for a Foundation Trainee and a CMT for each 4 month placement. Dr Hasan is a clinical supervisor for a Foundation Trainee for each placement.

Medical Oncology Registrars:

Active teaching and training for Specialty Registrars Including: one to one tutorials, work place based assessments, 3 team clinical supervision reports per year.

Dr Braun is Training Programme Director for Medical Oncology attending the national SAC meetings, chairing local STSC meetings, organising local ARCPs and providing externality for ARCPs in other deaneries. Dr Braun is Educational Supervisor and mentor to Medical Oncology Trainees.

International:

Ain Shams University Conference, Cairo November 2014 – Dr Braun invited speaker